HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Endoglin as a target of antitumor therapy].

Abstract
Blood vascular supply significantly affects progression of tumor growth. Inhibition of endothelial cell proliferation by antiangiogenic drugs should lead to growth arrest of both primary tumors and metastases. During the course of lengthy therapy, endothelial cells may, however, become refractory to the action of antiangiogenic agents. Novel approaches to anticancer treatment should explore the issue of drug resistance shown by endothelial cells. One possible therapeutic solution might be tumor immunotherapy directed against antigens expressed on the surface of endothelial cells which co-form tumor blood vasculature. Such therapy is supposed to break immune tolerance to own antigens and to eliminate tumor blood vessel endothelial cells by activating cytotoxic T lymphocytes. This kind of response can be obtained against endoglin (CD105). Endoglin is overexpressed in proliferating endothelial cells which line tumor blood vessels. Presence of endoglin in solid tumor blood vessels has prognostic value in cancer treatment. CD105 is also expressed by certain cancer cells (prostate, melanoma and Ewing sarcoma). It appears that therapeutic strategies directed against endoglin allow several mechanisms of resistance to antiangiogenic drugs to be omitted. The therapeutic approach that we propose, i.e. a tumor blood vessel-destroying strategy combined with immunotherapy, may become an effective therapeutic tool. 
AuthorsMagdalena Jarosz, Stanisław Szala
JournalPostepy higieny i medycyny doswiadczalnej (Online) (Postepy Hig Med Dosw (Online)) Vol. 67 Pg. 79-89 (Feb 19 2013) ISSN: 1732-2693 [Electronic] Poland
Vernacular TitleEndoglina jako cel terapii przeciwnowotworowej.
PMID23475485 (Publication Type: Journal Article, Review)
Chemical References
  • Angiogenesis Inhibitors
  • Antigens, CD
  • ENG protein, human
  • Endoglin
  • Receptors, Cell Surface
Topics
  • Angiogenesis Inhibitors (pharmacology)
  • Animals
  • Antigens, CD (drug effects, immunology)
  • Drug Resistance, Neoplasm (drug effects, immunology)
  • Endoglin
  • Endothelial Cells (drug effects, immunology)
  • Humans
  • Immune Tolerance (drug effects)
  • Immunotherapy
  • Neoplasms (blood supply, drug therapy, immunology)
  • Receptors, Cell Surface (drug effects, immunology)
  • T-Lymphocytes, Cytotoxic (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: